Cutaneous manifestations of end-stage renal disease

2015 ◽  
Author(s):  
Timur A. Galperin ◽  
Kieron S. Leslie ◽  
Antonia J. Cronin
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Skin Diseases ◽  
Treatment Options ◽  
Electrolyte Imbalance ◽  
Cutaneous Manifestations ◽  
Metastatic Calcification ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

A broad range of skin diseases occur in patients with end-stage renal disease. Some of these conditions are benign, and make little impact on patients’ lives. Others, however, have a greater impact on quality of life, may be physically disabling, and even life-threatening. Mostly, they result from a combination of factors, such as electrolyte imbalance and co-morbid disease. Uraemic pruritus is the most commonly troublesome and an approach to it is presented. Other non-specific skin manifestations of CKD include skin-colour changes, xerosis, half-and-half nails Specific manifestations include acquired perforating dermatosis, bullous dermatoses, metastatic calcification, and nephrogenic systemic fibrosis. Pathophysiology, clinical presentation, diagnosis, and treatment options are discussed.

scholarly journals Real-world evidence and optimization of vocal dysfunction in end-stage renal disease patients with secondary hyperparathyroidism

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Geng-He Chang ◽  
Fong-Fu Chou ◽  
Ming-Shao Tsai ◽  
Yao-Te Tsai ◽  
Ming-Yu Yang ◽  
...  
Keyword(s):  
Renal Disease ◽  
Secondary Hyperparathyroidism ◽  
Real World ◽  
End Stage Renal Disease ◽  
Cox Regression ◽  
Electrolyte Imbalance ◽  
Research Database ◽  
Cox Regression Analysis ◽  
Stage Renal Disease ◽  
End Stage

AbstractPatients with end-stage renal disease (ESRD) may demonstrate secondary hyperparathyroidism (SHPT), characterized by parathyroid hormone oversecretion in response to electrolyte imbalance (e.g., hypocalcemia and hyperphosphatemia). Moreover, this electrolyte imbalance may affect vocal cord muscle contraction and lead to voice change. Here, we explored the effects of SHPT on the voices of patients with ESRD. We used data of 147,026 patients with ESRD from the registry for catastrophic illness patients, a sub-database of Taiwan National Health Insurance Research Database. We divided these patients into 2 groups based on whether they had hyperparathyroidism (HPT) and compared vocal dysfunction (VD) incidence among them. We also prospectively included 60 ESRD patients with SHPT; 45 of them underwent parathyroidectomy. Preoperatively and postoperatively, voice analysis was used to investigate changes in vocal parameters. In the real-world database analysis, the presence of HPT significantly increased VD incidence in patients with ESRD (p = 0.003): Cox regression analysis results indicated that patients with ESRD had an approximately 1.6-fold increased VD risk (p = 0.003). In the clinical analysis, the “jitter” and “shimmer” factors improved significantly after operation, whereas the aerodynamic factors remained unchanged. In conclusion, SHPT was an independent risk factor for VD in patients with ESRD, mainly affecting their acoustic factors.

Preferences of Nephrologists among End-Stage Renal Disease Treatment Options

1985 ◽  
Vol 5 (6) ◽  
pp. 470-475 ◽  
Author(s):  
Cindy Dunham ◽  
William D. Mattern ◽  
William C. McGaghie
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Treatment Options ◽  
Disease Treatment ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis

Sarcoma ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-5 ◽  
Author(s):  
Sheron Latcha ◽  
Robert G. Maki ◽  
Gary K. Schwartz ◽  
Carlos D. Flombaum
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Response To Therapy ◽  
Common Side Effect ◽  
Pharmacokinetic Data ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage ◽  
Metastatic Sarcoma ◽  
Radiographic Improvement

Background. Pharmacokinetic data on clearance of ifosfamide in hemodialysis patients are limited. Consequently, these patients are excluded from therapy with this agent. We review the outcomes for patients at our institution with end stage renal disease on dialysis who received ifosfamide for metastatic sarcoma.Patients and Methods. We treated three patients with end stage renal disease on hemodialysis with escalating doses of ifosfamide. Data on radiographic response to therapy, WBC and platelet counts, signs or symptoms of infection, neuropathy and bladder toxicity are reported. Starting doses of ifosfamide were based on review of the literature available with subsequent modifications based on each patient's prior exposure to myelosuppressive agents and on symptoms of neurotoxicity and the degree of myelosuppression following each cycle of chemotherapy.Results. Myelosuppression was the most common side effect from therapy, but no patient developed a life threatening infection, neurotoxicity, or hematuria. One patient developed epistaxis in the setting of thrombocytopenia while on warfarin therapy. All patients had clinical evidence for therapeutic response and two had documented radiographic improvement following ifosfamide administration.Conclusion. Ifosfamide can be used safely in combination with hemodialysis in patients with end stage renal disease.

Hemorrhage as a life-threatening complication after valve replacement in end-stage renal disease patients

2015 ◽  
Vol 63 (7) ◽  
pp. 386-394 ◽  
Author(s):  
Taro Nakatsu ◽  
Nobushige Tamura ◽  
Shigeki Yanagi ◽  
Shoichi Kyo ◽  
Takaaki Koshiji ◽  
...  
Keyword(s):  
Renal Disease ◽  
Valve Replacement ◽  
End Stage Renal Disease ◽  
Life Threatening ◽  
Life Threatening Complication ◽  
Stage Renal Disease ◽  
End Stage

Patients' Preferences Regarding Choice of End-Stage Renal Disease Treatment Options

2013 ◽  
Vol 37 (4) ◽  
pp. 359-369 ◽  
Author(s):  
Abdelmouttalib Maaroufi ◽  
Coraline Fafin ◽  
Sophie Mougel ◽  
Guillaume Favre ◽  
Barbara Seitz-Polski ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Treatment Options ◽  
Disease Treatment ◽  
Stage Renal Disease ◽  
End Stage

Decisional conflict between treatment options among end-stage renal disease patients evaluated for kidney transplantation

2017 ◽  
Vol 31 (7) ◽  
pp. e12991 ◽  
Author(s):  
Laura McPherson ◽  
Mohua Basu ◽  
Jennifer Gander ◽  
Stephen O. Pastan ◽  
Sumit Mohan ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Treatment Options ◽  
Decisional Conflict ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals CUTANEOUS MANIFESTATIONS IN PATIENTS UNDERGOING HAEMODIALYSIS FOR END STAGE RENAL DISEASE

2015 ◽  
Vol 4 (34) ◽  
pp. 5872-5876 ◽  
Author(s):  
Gupta Uphar ◽  
Raghavendra Prasad B N ◽  
Vidyasagar C R ◽  
Vaishnavi Alam ◽  
Harish B V
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cutaneous Manifestations ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Incidence of cutaneous manifestation in patients with end stage renal disease

2017 ◽  
Vol 4 (4) ◽  
pp. 989
Author(s):  
Khileshwar Singh ◽  
Amit Thakur ◽  
Kamlesh Dhruv
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Chronic Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cutaneous Manifestation ◽  
Renal Diseases ◽  
Cutaneous Manifestations ◽  
Stage Renal Disease ◽  
End Stage

Background: Kidney failure as well as renal diseases is the most important health problems affecting the middle and old age population all over the world. They were supposed to be fatal till recently. The objective of this study was to study incidence of cutaneous manifestation in patients with end stage renal disease.Methods: A hospital based cross sectional study was carried out from July 2012 to June 2013 in the Department of General Medicine, Late Baliram Kashyap Memorial Government Medical College, Jagdalpur, Chhattisgarh, India. It was possible to study a total of 50 cases of cutaneous manifestations that are already known cases of end stage renal disease. All patients with skin lesion were evaluated by history, clinical examination (systemic and dermatological), biopsy and other relevant investigations procedure for skin disease during the course of current renal disease and their stay in the hospital.Results: The incidence of cutaneous manifestations among patients with acute renal failure was zero. It was 86% among patients with chronic renal failure. The most common manifestation was pruritus in 14% of cases followed by oral candidiasis in 4% of cases. Next common was scabies in 6% of cases and this was followed by herpes zoster and Tinea cruris in 4% of cases each. Folliculitis was seen in only one case. It was seen that all types of cutaneous manifestations were present only in patients with chronic renal failure, whereas patients of acute renal failure did not show any sort of cutaneous manifestations.Conclusions: Chronic renal failure was observed as the important cause of cutaneous manifestations seen in patients with end stage renal disease. No cases were seen in patients with acute renal failure. Thus, it is important that patients with acute renal failure take proper precautions to avoid cutaneous manifestations up to the extent possible.

Sign in / Sign up

Export Citation Format

Share Document